Goldman Sachs
VYGR icon

Goldman Sachs’s Voyager Therapeutics VYGR Stock Holding History

Goldman Sachs’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Sell
338,477
-89,120
-21% -$338K ﹤0.01% 5080
2026
Q1 		$1.65M Buy
427,597
+124,464
+41% +$490K ﹤0.01% 4698
2025
Q4 		$1.19M Buy
303,133
+5,560
+2% +$24.6K ﹤0.01% 5001
2025
Q3 		$1.39M Buy
297,573
+16,657
+6% +$60.3K ﹤0.01% 4800
2025
Q2 		$874K Buy
280,916
+57,541
+26% +$186K ﹤0.01% 4798
2025
Q1 		$755K Sell
223,375
-67,877
-23% -$317K ﹤0.01% 4911
2024
Q4 		$1.65M Sell
291,252
-37,074
-11% -$239K ﹤0.01% 4450
2024
Q3 		$1.92M Sell
328,326
-115,658
-26% -$841K ﹤0.01% 4188
2024
Q2 		$3.51M Buy
443,984
+62,275
+16% +$522K ﹤0.01% 3485
2024
Q1 		$3.55M Buy
381,709
+201,684
+112% +$1.7M ﹤0.01% 3397
2023
Q4 		$1.52M Buy
180,025
+38,906
+28% +$282K ﹤0.01% 4128
2023
Q3 		$1.09M Buy
141,119
+58,700
+71% +$536K ﹤0.01% 4210
2023
Q2 		$944K Sell
82,419
-91,691
-53% -$949K ﹤0.01% 4377
2023
Q1 		$1.34M Buy
174,110
+104,364
+150% +$830K ﹤0.01% 4167
2022
Q4 		$425K Sell
69,746
-16,608
-19% -$94.4K ﹤0.01% 4962
2022
Q3 		$512K Sell
86,354
-23,487
-21% -$150K ﹤0.01% 4956
2022
Q2 		$649K Sell
109,841
-3,719
-3% -$25.1K ﹤0.01% 4901
2022
Q1 		$865K Buy
113,560
+80,277
+241% +$358K ﹤0.01% 4939
2021
Q4 		$90K Sell
33,283
-22,664
-41% -$77.3K ﹤0.01% 6165
2021
Q3 		$147K Sell
55,947
-118,242
-68% -$384K ﹤0.01% 5831
2021
Q2 		$720K Buy
174,189
+120,239
+223% +$545K ﹤0.01% 4995
2021
Q1 		$254K Sell
53,950
-229,629
-81% -$1.57M ﹤0.01% 5508
2020
Q4 		$2.03M Buy
283,579
+76,075
+37% +$731K ﹤0.01% 3721
2020
Q3 		$2.21M Sell
207,504
-158,050
-43% -$1.86M ﹤0.01% 3488
2020
Q2 		$4.61M Sell
365,554
-54,570
-13% -$635K ﹤0.01% 2854
2020
Q1 		$3.84M Buy
420,124
+1,834
+0.4% +$21.1K ﹤0.01% 2849
2019
Q4 		$5.83M Buy
418,290
+6,602
+2% +$96K ﹤0.01% 2836
2019
Q3 		$7.08M Buy
411,688
+54,024
+15% +$1.13M ﹤0.01% 2594
2019
Q2 		$9.74M Buy
357,664
+64,746
+22% +$1.48M ﹤0.01% 2376
2019
Q1 		$5.61M Buy
292,918
+59,274
+25% +$772K ﹤0.01% 2884
2018
Q4 		$2.2M Sell
233,644
-15,194
-6% -$195K ﹤0.01% 3471
2018
Q3 		$4.71M Buy
248,838
+82,324
+49% +$1.58M ﹤0.01% 3034
2018
Q2 		$3.25M Buy
166,514
+116,584
+233% +$2.3M ﹤0.01% 3263
2018
Q1 		$938K Buy
49,930
+19,522
+64% +$422K ﹤0.01% 4094
2017
Q4 		$505K Buy
30,408
+2,236
+8% +$38.3K ﹤0.01% 4826
2017
Q3 		$580K Buy
28,172
+11,124
+65% +$126K ﹤0.01% 4994
2017
Q2 		$153K Buy
17,048
+1,399
+9% +$14.1K ﹤0.01% 5937
2017
Q1 		$207K Sell
15,649
-291,446
-95% -$3.54M ﹤0.01% 5716
2016
Q4 		$3.91M Sell
307,095
-287,327
-48% -$3.69M ﹤0.01% 3263
2016
Q3 		$7.14M Sell
594,422
-94,823
-14% -$1.28M ﹤0.01% 2732
2016
Q2 		$7.58M Sell
689,245
-108,572
-14% -$1.33M ﹤0.01% 2537
2016
Q1 		$6.96M Sell
797,817
-17,543
-2% -$199K ﹤0.01% 2493
2015
Q4 		$17.9M Buy
+815,360
New +$18.8M 0.01% 1835

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs's VYGR Position: Q2 2026 in Review

Goldman Sachs reduced its Voyager Therapeutics (VYGR) stake by 21% in Q2 2026, selling an estimated $338K and leaving 338,477 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #5080.

Goldman Sachs first reported a position in VYGR in Q4 2015 and has held it in 43 quarters since. The position peaked at $17.9M in Q4 2015. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Goldman Sachs held 338,477 shares of Voyager Therapeutics worth $1.18M as of Q2 2026.
  • Goldman Sachs sold 89,120 Voyager Therapeutics shares in Q2 2026, an estimated $338K.
  • Voyager Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5080 holding.
  • Goldman Sachs first reported a position in Voyager Therapeutics in Q4 2015 and has held it in 43 quarters since.
  • Goldman Sachs's Voyager Therapeutics position peaked at $17.9M in Q4 2015.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.